The purpose of this funding opportunity announcement (FOA) is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science.
This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this FOA. This FOA does not propose to support commercial production
Companion FOA: PAR-22-242, Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
- Letter of Intent: 30 days prior to application due date.
- R01 Deadlines: October 31, 2022, then standard dates: Feb. 5, Jun. 5, Oct. 5.
- AIDS Deadlines: Jan. 7, May 7, Sep. 7.
PAR-22-243 Expiration Date: September 08, 2025